POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Clinical trials for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) explained in plain language.
Never miss a new study
Get alerted when new POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) trials appear
Sign up with your email to follow new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye drug regimen could mean fewer shots for PCV patients
Disease control Recruiting nowThis study tests a higher dose of the eye medication aflibercept (8 mg) given on a personalized schedule for people with a specific type of wet macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this approach can safely extend the time betw…
Matched conditions: POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Phase: PHASE3 • Sponsor: Yeungnam University College of Medicine • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
New eye drug regimen aims to extend time between treatments for PCV patients
Disease control Recruiting nowThis study is testing a personalized treat-and-extend approach using faricimab for people newly diagnosed with polypoidal choroidal vasculopathy (PCV), a form of age-related macular degeneration. The goal is to see if this regimen can control the disease while allowing longer int…
Matched conditions: POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Phase: PHASE3 • Sponsor: Yeungnam University College of Medicine • Aim: Disease control
Last updated May 22, 2026 14:05 UTC